Oncternal Therapeutics Reverse Merges with GTx
Shots:
- With the closure of the transaction- Oncternal Therapeutics will be listed on Nasdaq under the ticker ONCT
- Oncternal’s stockholders will hold 75% of the shares of combined company and GTx will retain 25% of shares. GTx stockholders will receive 50% non-transferable contingent value rights (CVR) from the grant- sale or transfer of rights to SARD
- The newly merged company have strong Octernal’s oncology portfolio with GTx’s Selective Androgen Receptor Degrader (SARD) technology for castration-resistant prostate cancer
Ref: Oncternal | Image: GMP news
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com